Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous MK-3475A versus intravenous pembrolizumab with chemotherapy in first-line metastatic non-small cell lung cancer
jRCT2031230049Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: Cycle 1 AUC0-6 weeks and Steady-state Cycle 3 trough concentration. Started Jun 2023; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031230049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230049.